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Human monomeric mitochondrial phenylalanyl-tRNA synthetase (mitPheRS)
is an enzyme that catalyzes the charging of tRNA with the cognate amino acid
phenylalanine. Human mitPheRS is a chimera of the bacterial -subunit of
PheRS and the B8 domain of its -subunit. Together, the -subunit and the
‘RNP-domain’ (B8 domain) at the C-terminus form the minimal structural set to
construct an enzyme with phenylalanylation activity. The recombinant human
mitPheRS was purified to homogeneity and crystallized in complex with
phenylalanine and ATP. The crystals diffracted to 2.2 Å resolution and belonged
to space group P212121, with unit-cell parameters a = 55, b = 90, c = 96 Å.
1. Introduction
Covalent attachment of amino acids to their cognate tRNAs is the
first step in protein biosynthesis catalyzed by aminoacyl-tRNA
synthetases (aaRSs; reviewed by Francklyn et al., 2002). The aaRSs
play a crucial role in the maintenance of faithful translation,
promoting close control over the two-step aminoacylation reaction.
In some cases, the aaRSs are incapable of discriminating between
structurally similar amino acids and misacylation of tRNA with a
noncognate amino acid occurs. To enhance the accuracy of aa-tRNA
synthesis, an editing activity against mis-activated amino acids and/or
mischarged aa-tRNAs has evolved (reviewed by Hendrickson &
Schimmel, 2003; Jakubowsky, 2004).
In eukaryotes, protein synthesis occurs not only in the cytoplasm
but also in different organelles, such as mitochondria and chloro-
plasts. In the majority of organisms, mitochondrial aaRSs (mit-
aaRSs) are encoded in the nucleus and then post-translationally
transported into the organelle. In a few cases, mit-aaRSs are identical
to their cytosolic counterparts, as in the case of yeast mitValRS (Wang
et al., 2003; Chatton et al., 1988) and mitHisRS (Natsoulis et al., 1986),
human mitGlyRS (Sissler et al., 2005) and plant mitThrRS (Souciet et
al., 1999). In other cases, eukaryotic mit-aaRSs exhibit higher
homology to bacterial enzymes than to their cytosolic counterparts
from the same organism (Spencer et al., 2004).
Human mitPheRS also exhibits higher homology to the bacterial
PheRSs than to the corresponding cytosolic enzyme. Like other
PheRS, the human mitochondrial enzyme has the characteristic
sequence motifs of a class II aaRS. However, while the bacterial
enzyme is an ()2 heterodimer with a total length of 2270 residues
(Mosyak et al., 1995; Goldgur et al., 1997), the mitPheRS homolog is a
415 amino-acid single-chain enzyme and is in fact a chimera of the
-subunit and the B8 domain from the -subunit of the bacterial
PheRS (Bullard et al., 1999). It has been suggested (Bullard et al.,
1999) that the mitochondrial enzyme is a simplified version of the
synthetase that solely serves the aminoacylation function, while the
prokaryotic and eukaryotic cytosolic enzymes have developed addi-
tional functions inside the cell (e.g. Dou et al., 2001; Ivanov et al.,
2000). It might also be speculated that this simplification evolved
evolutionarily because of the challenges involved with the import,
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folding and assembly of a heterodimeric synthetase during the post-
translational transport of the protein through the mitochondrial
membrane.
The three-dimensional structure of the cytoplasmic Thermus
thermophilus PheRS has been determined both in the apo form and
with the substrates phenylalanine, PheAMP and tRNAPhe (Fishman
et al., 2001; Goldgur et al., 1997; Reshetnikova et al., 1999). It was
shown that the amino-acid-binding pocket accommodates not only
the cognate amino acid phenylalanine, but also the noncognate
tyrosine and the unnatural amino acid p-chlorophenylalanine (Kotik-
Kogan et al., 2005). Both bacterial and eukaryotic cytoplasmic
PheRSs have been shown to misactivate l-tyrosine, but do not attach
this amino acid stably to tRNAPhe (Roy et al., 2004; Kotik-Kogan et
al., 2005; Sasaki et al., 2006). Rather, these enzymes hydrolyze the
misacylated Tyr-tRNAPhe in the editing site located at the interface of
the B3 and B4 domains. Yeast mitPheRS also misactivates l-tyrosine,
although its selectivity is one order of magnitude higher than that of
the yeast cytosolic PheRS (Roy et al., 2005). However, the yeast and
human mitPheRSs are unable to deacylate Tyr-tRNAPhe owing to the
absence of the editing module associated with the B3 and B4
domains. No trans-editing has been detected in mitochondrial
extracts, indicating that the quality control of protein synthesis
normally gained by proofreading Tyr-tRNAPhe is missing from
mitochondria (Roy et al., 2005).
The lack of post-transfer editing activity in mitochondrial aaRS
may be a general phenomenon, although it may be compensated for
to some extent by increased specificity for the cognate amino acid, as
has been demonstrated for a human mitLeuRS (Lue & Kelley, 2005).
This suggests that certain stages in the translation of the genetic code
in mitochondria might generally be more error-prone than other
translational systems. Poor fidelity in translation can lead to the
accumulation of misfolded proteins and in turn result in cell death
(Lee et al., 2006). On the other hand, in mitochondria only a small
fraction of proteins are synthesized inside the organelle (e.g. 13
proteins in human mitochondria), while the majority of proteins are
post-translationally imported following synthesis in the cell cyto-
plasm. One can speculate that the mitochondria can tolerate the low
fidelity in translation, thus gaining a simplified (and less energy-
consuming) translational machinery.
Information on the three-dimensional structure of mitPheRS is
essential to provide the structural basis of the function of this unusual
enzyme. The insights provided by structural studies will shed light on
the increased amino-acid specificity and novel mode of tRNA binding
to human mitPheRS. The solution of the three-dimensional structure
of this enzyme is even more important in view of recent findings
showing that at least 150 known human genetic diseases originate
from mutations in the mitochondrial translational machinery (Jacobs
& Turnbull, 2005; Wittenhagen & Kelley, 2003; Schapira, 2006). Here,
we report the purification and crystallization of the human mitPheRS,
as well as preliminary crystallographic characterization of the
enzyme.
2. Materials and methods
2.1. Protein expression and purification
The residues predicted to be present in the mature form of human
mitPheRS were originally cloned in a pET-21c(+) vector as described
by Bullard et al. (1999). This vector produces a C-terminally His-
tagged mature mitPheRS protein. However, the construct thus
expressed and purified appeared to consist of approximately 20%
dimeric and 80% monomeric forms [as judged by the elution of the
construct from a 25 ml size-exclusion analytical Superdex 200 FPLC
column (GE Healthcare) calibrated with the Sigma Gel Filtration
Molecular Weight Marker Kit (No. MWGF70); data not shown]. The
His tag was therefore removed from the construct in order to avoid
any possible oligomeric heterogeneity that might interfere with
crystallization. The PCR product encompassing the gene encoding
mitPheRS (415 residues in total) without the His tag was cloned into
the pET-21c(+) vector using the XbaI and XhoI restriction sites that
had been incorporated into the PCR primers. DNA sequencing was
performed on an Applied Biosystems Model 373A DNA sequencer
using appropriate primers. The vector was transformed into Escher-
ichia coli Rosetta DE3 strain cells (Novagen). A number of fresh
colonies were inoculated into 3 l LB medium supplemented with
50 mg ml1 ampicillin and cultured at 310 K to an OD600 of 0.6–0.8.
The cells were then induced with 0.5 mM IPTG and cultured over-
night at 298 K. Cells were harvested by centrifugation at
4000 rev min1 for 30 min and stored at 193 K.
For protein purification, the cells were resuspended in lysis buffer
(25 mM Tris–HCl pH 8, 400 mM NaCl, 7 mM MgCl2, 10% glycerol,
10 mM 2-mercaptoethanol). After disruption by pulsed sonication,
cell debris was removed by ultracentrifugation at 30 000 rev min1
for 0.5 h. DNA was then precipitated by a 10 min incubation with
1.3% streptomycin sulfate followed by ultracentrifugation at
30 000 rev min1 for 0.5 h. Because of the pI of the mitPheRS (the
theoretical value is 6.4), the protein was poorly retained on the
DEAE-Sepharose column (Bullard et al., 1999). Satisfactory binding
of mitPheRS to the DEAE resin was achieved by increasing the pH
value of the buffer to 8.6. The clear cell extract (892 mg protein) was
dialyzed against DEAE-loading buffer (20 mM Tris–HCl pH 8.6,
20 mM NaCl, 7 mM MgCl2, 10% glycerol, 10 mM 2-mercapto-
ethanol), applied onto a 50 ml DEAE-Sepharose CL-6B 250 
25 mm ion-exchange column (GE Healthcare) and washed with
250 ml DEAE-loading buffer at 277 K. The retained mitPheRS was
eluted from the DEAE-Sepharose column using a linear 500 ml
gradient (20–200 mM) of NaCl in DEAE-loading buffer. Fractions
(9 ml) were collected at a flow rate of 1.5 ml min1 at 277 K. The
mitPheRS eluted at about 100 mM NaCl. Fractions containing
mitPheRS were identified by SDS–PAGE (Fig. 1), pooled, dialyzed
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Figure 1
SDS–PAGE analysis of the overproduced human mitPheRS following the
purification procedure. Samples were analyzed on 12%(w/v) polyacrylamide gels
and the proteins were visualized by staining with Coomassie Blue. All lanes were
loaded with 20 mg protein. Lane A, crude lysate; lane B, material following
purification on a DEAE-Sepharose column; lane C, sample of the mitPheRS
preparation following purification on the heparin column; lane D, purified
mitPheRS obtained by purification on Superdex-200.
against heparin-loading buffer (20 mM Tris–HCl pH 8, 20 mM NaCl,
7 mM MgCl2, 10 mM 2-mercaptoethanol) and loaded onto a 5 ml
HiTrap heparin-affinity column (25  16 mm, GE Healthcare).
MitPheRS was well retained by the column and was eluted as a single
peak using a linear 400 ml gradient (20–400 mM) of NaCl in heparin-
loading buffer. The flow rate was 1 ml min1 and 7 ml fractions were
collected. Fractions containing mitPheRS were identified by SDS–
PAGE and pooled.
MitPheRS was then concentrated by adding 35% ammonium
sulfate to the pooled fractions and trapping the protein on a 1 ml TSK
hydrophobic interaction column (Tosoh). MitPheRS was eluted from
this column with heparin-loading buffer in a final volume of about
2 ml and then loaded onto a 600  16 mm size-exclusion HiLoad
Superdex 200 column (GE Healthcare). Elution was performed with
size-exclusion buffer (50 mM Tris–HCl pH 8, 1 M NaCl, 5 mM MgCl2,
5% glycerol, 5 mM 2-mercaptoethanol). The purified protein eluted
from this column in a single symmetrical peak at a retention volume
of 79 ml. The Sigma Gel Filtration Molecular Weight Markers Kit
(No. MWGF70) was used to determine the molecular weight of the
mitPheRS. The retention volume of mitPheRS (79 ml) corresponded
to a protein with an approximate molecular weight of 48 kDa, which
in turn indicated that the purified mitPheRS was monomeric. It was
then concentrated on a 1 ml TSK hydrophobic interaction column, as
described above, to a final concentration of 6 mg ml1 and dialyzed
against crystallization buffer (20 mM Tris–HCl pH 8, 100 mM NaCl,
7 mM MgCl2, 5 mM 2-mercaptoethanol, 1 mM EDTA and 0.0065%
NaN3). The yield of mitPheRS was about 4 mg from 1 l LB medium.
The protein was stored in small aliquots and flash-frozen at 193 K; it
was stable when thawed.
The protein concentration was determined by the Bradford assay
using bovine serum albumin as a standard. SDS–PAGE was
performed on 12% slab gels with 5% stacking gels (Bio-Rad Mini-
Protein II system) and stained with Coomassie Brilliant Blue.
2.2. Aminoacylation assay
MitPheRS activity was determined in the tRNA-aminoacylation
reaction using a trichloroacetic acid (TCA) precipitation assay.
Reaction mixtures contained 25 mM Tris–HCl pH 8.5, 10 mM MgCl2,
5 mM ATP, 2 mM l-[3H]-phenylalanine (54 Ci mmol1) and
5 mg ml1 baker’s yeast tRNAbulk (Sigma). The reaction was started
by the addition of an amount of protein that causes a linear increase
in phenylalanylation within the first 2 min. The reaction was carried
out at 310 K. The velocity of the esterification was measured by the
rate of l-[3H]-phenylalanine incorporation into tRNA. At the
appropriate times, aliquots were spotted onto paper filters impreg-
nated with TCA. The paper filters were then washed and dried, after
which the TCA-insoluble radioactivity was measured by liquid-
scintillation counting.
2.3. Crystallization
Once purified, mitPheRS was screened against Crystal Screens I
and II, Index and SaltRx sparse-matrix crystallization screens
(Hampton Research, USA). Crystallization assays were carried out
with the apo form of the enzyme and three holo forms: mitPheRS–
phenylalanine, mitPheRS–phenylalanine–ATP and mitPheRS–ATP.
Screening was performed at 292 and 277 K in the standard 2 ml
hanging-drop setup (1 ml protein mixed with 1 ml reservoir solution;
700 ml reservoir solution), as well as in 0.3 ml (0.15 ml protein mixed
with 0.15 ml reservoir solution; 70 ml reservoir solution) sitting drops
using the Mosquito Crystallization Robot (TTP LabTech; Albeck et
al., 2006). Crystals of the mitPheRS complex with phenylalanine and
ATP appeared in 0.3 ml sitting drops containing 1.8 M sodium acetate
buffer pH 7, 100 mM bis-Tris propane pH 7 at 292 K. The crystals
appeared over two months and had a needle shape; their size was less
then 0.03 mm in the longest direction.
Variation of the amount of the ligands and the use of additives
(Additive Screens I and II, Hampton Research) and seeding were
used to optimize the crystallization conditions. Final crystals were
obtained in 3.5 ml hanging drops containing 3.1 mg ml1 (65 mM)
mitPheRS, 360 mM ATP, 360 mM phenylalanine, 1 mM DTT, 60 mM
MgCl2, 60 mM bis-Tris propane pH 7 and 1 M sodium acetate pH 7
incubated over a 0.5 ml reservoir solution containing 2 mM DTT,
100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7 at
292 K and streak-seeded from the previous crystallization experi-
ments. MitPheRS was mixed with the ligands immediately prior to
setting up the crystallization drops.
2.4. Data collection and processing
For data collection at cryogenic temperature (100 K), the crystals
were transferred to a mother-liquor solution containing 25% glycerol,
mounted on a cryogenic loop (Teng, 1990) and flash-cooled using an
Oxford Cryostream (Cosier & Glaser, 1986) low-temperature device.
A complete data set to 2.2 Å was collected from a single crystal using
a Rigaku R-AXIS IV++ imaging-plate area detector mounted on a
Rigaku RU-H3R rotating-anode generator equipped with a multi-
layer focusing mirror from Osmic and Cu X-rays ( = 1.5418 Å). The
diffraction data were integrated, scaled and reduced using the HKL-
2000 (Otwinowski & Minor, 1997) program package (Table 1).
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Table 1
Data-collection statistics.
Values in parentheses are for the outermost shell.
Space group P212121
Unit-cell parameters (Å, ) a = 54.9, b = 90.1, c = 95.8,
 = 90,  = 90,  = 90
Resolution (Å) 50–2.2 (2.24–2.2)
Completeness (%) 100 (100)
hIi/h(I)i 20.7 (3.1)
Rmerge (based on intensities) 0.07 (0.44)
Redundancy 4.4 (4.4)
No. of unique reflections 24973 (1198)
Figure 2
Diffraction-quality crystals of human mitPheRS grown using the hanging-drop
method with the use of streak-seeding. Crystals reached their maximum dimensions
of 0.16  0.1  0.08 mm within 2–3 weeks.
3. Results and discussion
Mature untagged monomeric human mitPheRS protein composed of
415 amino acids and with a molecular weight of 48 kDa and a
theoretical pI of 6.4 has been overexpressed in E. coli cells and
purified using three successive chromatographic steps: (i) ion
exchange on Fast Flow DEAE-Sepharose resin, (ii) affinity chro-
matography on heparin resin and (iii) size exclusion on Superdex-200
(Fig. 1). Using this purification procedure, we achieved a 30-fold
purification of mitPheRS (Table 2). The total yield of mitPheRS
provided about 4 mg of purified protein from 1 l LB medium. The
purity of human mitPheRS was assessed by SDS–PAGE, where it
migrated as a single 50 kDa band.
No crystals of the human mitPheRS apo form were detected in any
of the sparse-matrix crystallization screens tested. Crystals of
mitPheRS complexed with phenylalanine and ATP appeared in a
single screening condition and could be grown over the course of a
few days when streak-seeded from the initial successful crystallization
screening experiment. The crystals had a bipyramidal morphology,
diffracted to 2.7 Å resolution and exhibited orthorhombic symmetry.
Further refinement of the crystallization conditions by the inclusion
of 60 mM MgCl2 in the mother liquor yielded crystals with prismatic
morphology and orthorhombic symmetry and with unit-cell para-
meters that were virtually the same as those of the bipyramidal
crystals (Fig. 2). These crystals appeared within a week and grew to
their final dimensions (0.16  0.1  0.05 mm) in the following three
weeks. The crystals show a diffraction limit of beyond 2.2 Å resolu-
tion. A complete data set was collected to 2.2 Å with an Rmerge of
0.071% from a single crystal (see Table 1 for data-collection statis-
tics). Examination of the systematic absences indicated that the
crystals belong to the orthorhombic space group P212121, with unit-
cell parameters a = 55, b = 90, c = 96 Å. This yields a calculated VM
value of 2.45 Å3 Da1 and a solvent content of 49.9%, assuming the
presence of one molecule in the asymmetric unit (Matthews, 1968).
The mitPheRS structure has been solved using the molecular-
replacement method implemented in Phaser (McCoy et al., 2005). The
crystal structure of bacterial phenylalanyl-tRNA synthetase from
T. thermophilus (PDB code 1pys) was used as the search model.
Crystallographic refinement of human mitPheRS is now in progress.
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Francklyn, C., Perona, J. J., Pütz, J. & Hou, Y. M. (2002). RNA, 8, 1363–1372.
Goldgur, Y., Mosyak, L., Reshetnikova, L., Ankilova, V., Lavrik, O.,
Khodyreva, S. & Safro, M. (1997). Structure, 5, 59–68.
Hendrickson, T. L. & Schimmel, P. (2003). Translational Mechanisms, edited
by J. Lapointe & L. Brakier-Gingras, pp. 34–64. Georgetown, TX, USA:
Landes Bioscience.
Ivanov, K. A., Moor, N. A., Ankilova, V. N. & Lavrik, O. I. (2000).
Biochemistry (Mosc.), 65, 436–441.
Jacobs, H. T. & Turnbull, D. M. (2005). Trends Genet. 21, 312–314.
Jakubowsky, H. (2004). The Aminoacyl-tRNA Synthetases, edited by M. Ibba,
C. Francklyn & S. Cusack, pp. 384–396. Georgetown, TX, USA: Landes
Bioscience.
Kotik-Kogan, O., Moor, N., Tworowski, D. & Safro, M. (2005). Structure, 13,
1799–1807.
Lee, J. W., Beebe, K., Nangle, L. A., Jang, J., Longo-Guess, C. M., Cook, S. A.,
Davisson, M. T., Sundberg, J. P., Schimmel, P. & Ackerman, S. L. (2006).
Nature (London), 443, 50–55.
Lue, S. W. & Kelley, S. O. (2005). Biochemistry, 44, 3010–3016.
McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. (2005).
Acta Cryst. D61, 458–464.
Matthews, B. (1968). J. Mol. Biol. 33, 491–497.
Mosyak, L., Reshetnikova, L., Goldgur, Y., Delarue, M. & Safro, M. G. (1995).
Nature Struct. Biol. 2, 537–547.
Natsoulis, G., Hilger, F. & Fink, G. R. (1986). Cell, 46, 235–243.
Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326.
Reshetnikova, L., Moor, N., Lavrik, O. & Vassylyev, D. (1999). J. Mol. Biol.
287, 555–568.
Roy, H., Ling, J., Alfonzo, J. & Ibba, M. (2005). J. Biol. Chem. 280, 38186–
38192.
Roy, H., Ling, J., Irnov, M. & Ibba, M. (2004). EMBO J. 23, 4639–4648.
Sasaki, H. M., Sekine, S., Sengoku, T., Fukunaga, R., Hattori, M., Utsunomiya,
Y., Kuroishi, C., Kuramitsu, S., Shirouzu, M. & Yokoyama, S. (2006). Proc.
Natl Acad. Sci. USA, 103, 14744–14749.
Schapira, A. (2006). Lancet, 368, 70–82.
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Table 2












Crude extract 892 6000 6.7 100
DEAE Sepharose 68 4500 66 9.8 75
HiTrap heparin 12 2180 180 27 36
Superdex 200 10 2000 200 30 33
† One unit of mitPheRS activity is defined as the amount of enzyme necessary to
catalyze the attachment of 1 nmol l-[3H]-phenylalanine to the tRNA in 1 min at 310 K.
